Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Revelation Biosciences (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting on December 3, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting on December 3, 2025. Shareholders who have not voted have until 11:59pm ET on December 2, 2025 to submit votes.
The company reaffirmed regulatory progress after successfully submitting and receiving acceptance of an end-of-phase 1 meeting package to FDA on November 20, 2025, and said it remains on track to hold that meeting later in 2025 to discuss the clinical and approval pathway for Gemini for acute kidney injury (AKI). The company also referenced its November 6, 2025 financial report covering the three and nine months ended September 30, 2025, highlighting top-line PRIME clinical results and $9.6 million gross proceeds from a September 2025 warrant inducement.
Positive
- Quorum reached for December 3, 2025 special meeting
- Voting deadline: 11:59pm ET December 2, 2025
- FDA end-of-phase 1 package accepted on November 20, 2025
- Top-line PRIME clinical results reported in November 2025
- $9.6 million gross proceeds from September 2025 warrant inducement
Negative
- None.
Details
News Market Reaction – REVB
On Dec 1, the day this news came out, REVB closed 0.15% above the previous close.
Data tracked by StockTitan Argus for the Dec 1 session.
Key Figures
- Special Meeting date
- December 3, 2025
- Scheduled Special Meeting of stockholders
- Voting deadline
- 11:59pm ET, December 2, 2025
- Cutoff for stockholders to submit votes
- End-of-phase 1 package date
- November 20, 2025
- Submission and FDA acceptance for Gemini AKI program
- Quarter end
- September 30, 2025
- Three and nine months financial reporting period
- Warrant inducement proceeds
- $9.6 million
- Gross proceeds from September 2025 warrant inducement
Historical Context
-
Quorum reached for Dec 3, 2025 Special Meeting and voting reminder.
-
FDA accepted end-of-phase 1 package for Gemini in AKI and PRIME data update.
-
Q3 2025 financials, PRIME top-line results, cash and warrant inducement proceeds.
-
Canceled adjourned Special Meeting and reset record date and meeting to Dec 3, 2025.
-
Adjourned Oct 15, 2025 Special Meeting to Oct 29, 2025 due to low participation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
clinical-stage medical
end-of-phase 1 meeting regulatory
FDA regulatory
acute kidney injury (AKI) medical
warrant inducement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. As a reminder, if you have not yet voted you have until 11:59pm ET tomorrow, December 2, 2025, to vote.
"I would like to thank all those that have voted for the December 3, 2025, Special Meeting and remind all those who have not yet voted to vote," said James Rolke, Chief Executive Officer, Revelation.
On November 20, 2025, Revelation Biosciences announced its successful submission and acceptance of the end-of-phase 1 meeting package to FDA, and that the company is on track to hold the meeting later this year. The primary purpose of this meeting is to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).
On November 6, 2025, the company reported its financial results for the three and nine months ended September 30, 2025. Highlights include groundbreaking top-line results from the PRIME clinical study and gross proceeds of
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.